PULSE BIOSCIENCES, INC.

Pulse Biosciences is a medical technology company specializing in the development and commercialization of bioelectric ablation systems. Its proprietary platform, the nPulse System, utilizes Nanosecond Pulsed-Field Ablation technology to deliver ultrashort electrical energy pulses that clear targeted cells nonthermally without causing thermal damage or scarring. The company's clinical and commercial pipeline centers on soft tissue and cardiac applications, notably the Vybrance Percutaneous Electrode System for soft tissue procedures such as thyroid nodule treatment, alongside specialized cardiac surgical clamps and circumferential endocardial catheter systems under clinical evaluation for atrial fibrillation. Target customers comprise healthcare providers, including cardiac surgeons, electrophysiologists, and interventional clinicians.

The company operates primarily within the United States, where it maintains early commercial evaluation sites and conducts multi-center clinical trials, while also pursuing clinical studies across European countries such as Italy, the Netherlands, Poland, Austria, and the Czech Republic. Pulse Biosciences maintains corporate offices located in Miami, Florida, with operations and research facilities situated in Hayward, California.

Summary of the business section of Pulse Biosciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 116 employees, of which most were located at our facility in Hayward, California.”